New-onset partial epilepsy in adults

Current Treatment Options in Neurology

Volumn 11, Issue 4, 2009, Pages 242-252

  Liu, Lynn ^a   Henry, J Craig ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VITAMIN D; ZONISAMIDE;

ALOPECIA; ANHEDONIA; ANOREXIA; ARTHRALGIA; ATAXIA; BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN DEPTH STIMULATION; BRAIN SURGERY; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COMPLEX PARTIAL SEIZURE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; COORDINATION DISORDER; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RELEASE; DRUG WITHDRAWAL; DUPUYTREN CONTRACTURE; DYSPHORIA; ELECTROENCEPHALOGRAM; FATIGUE; FOCAL EPILEPSY; FOOT EDEMA; FRACTURE; FROZEN SHOULDER; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GINGIVA HYPERPLASIA; HEADACHE; HIRSUTISM; HUMAN; HYPERAMMONEMIA; HYPONATREMIA; IRRITABILITY; KETOGENIC DIET; LANGUAGE DISABILITY; LETHARGY; LIFESTYLE MODIFICATION; MACROCYTIC ANEMIA; MEMORY DISORDER; METABOLIC ACIDOSIS; MOOD DISORDER; NAUSEA; NEPHROLITHIASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; RADIOSURGERY; RASH; REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TEMPORAL LOBECTOMY; TOXIC HEPATITIS; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; TREMOR; VAGUS NERVE STIMULATION; VOMITING; WEIGHT GAIN; WITHDRAWAL SEIZURE;

EID: 66749083839     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-009-0028-2     Document Type: Review

References (54)

1. Begley CE, Famulari M, Annegers JF, et al.: The cost of epilepsy in the United States: An estimate from population-based clinical and survey data. Epilepsia 2000, 41:342-351.
2. Kim LG, Johnson TL, Marson AG, Chadwick DW; MRC MESS Study Group: Prediction of risk of seizure recurrence after a single seizure and early epilepsy: Further results from the MESS trial. Lancet Neurol 2006, 5:317-322.
3. Marson A, Jacoby A, Johnson A, et al.: Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: A randomised controlled trial. Lancet 2005, 365:2007-2013.
4. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group). Neurology 1993, 43:478-483.
5. Musicco M, Beghi E, Solari A, Viani F: Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology 1997, 49:991-998.
6. Krumholz A, WiEbe S, Gronseth G, et al.: Practice parameter: evaluating an apparent unprovoked first seizure in adults (an evidence-based review). Neurology 2007, 69:1996-2007.
7. Harden CN, Huff JS, Schwartz TH, et al.: Reassessment: neuroimaging in the emergency patient presenting with seizure (an evidence-based review). Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007, 69:1772-1780.
8. Ross SD, Estok R, Chopra S, et al.: Management of newly diagnosed patients with epilepsy: A systematic review of the literature. Evidence Report/Technology Assessment No. 39. AHRQ Publication No. 01-E038. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
9. Hirtz D, AshwaE S, Berg A, et al.: Practice parameter: evaluating a first nonfebrile seizure in children. Neurology 2000, 55:616-623.
10. French JA, Kanner AM, Bautista J, et al.: Efficacy and tolerability of the new antiepileptic drugsRI: Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62:1252-1260.
11. Glauser T, Ben-Menachem E, Bourgeois B, et al.: ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006, 47:1094-1120.
12. Birbeck G, Hays RD, Cui X, et al.: Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 2002, 43:535-538.
13. Karceski S, Morrell MJ, Carpenter D: Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005, 7(Suppl 1):S1-S64.
14. Kwan P, Brodie MJ: Effectiveness of first antiepileptic drug. Epilepsia 2001, 42:1255-1260.
15. Berg AT, Langfitt J, Shinnar S, et al.: How long does it take for partial epilepsy to become intractable? Neurology 2003, 60:186-190.
16. Luciano AL, Shorvon SD: Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007, 62:375-381.
17. Callaghan BC, Anand K, Hesdorffer D, et al.: Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007, 62:382-389.
18. Deckers CLP, Grenton P, Sills GJ, Schmidt D: Current limitations of antiepileptic drug therapy: A conference review. Epilepsy Res 2003, 53:1-17.
19. Shorvon S: Handbook of Epilepsy Treatment. Oxford: Blackwell Science; 2000.
20. Hung SL, Chung WH, Jee SH, et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16:297-306.
21. Kamaliah MD, Zainal D, Mokhtar N, et al.: Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int J Dermatol 1998, 37:520-523.
22. Man CBL, Kwan P, Baum L, et al.: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007, 48:1015-1018.
23. Froscher W, Eichelbaum M, Gugler R, et al.: A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol 1981, 224:193-201.
24. Woo E, Chan YM, Yu YL, et al.: If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 1988, 29:129-139.
25. Jannuzzi G, Cian P, Fattore C, et al.: A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia 2000, 41:222-230.
26. Mattson RH, Gidal BE: Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004, 5(Suppl 2):S36-S40.
27. Andress DL, Ozuna J, Tirschwell D, et al.: Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 2002, 59:781-786.
28. Petty SJ, Paton LM, O'Brien TJ, et al.: Effect of antiepileptic drug medication on bone mineral measures. Neurology 2005, 65:1358-1365.
29. Ensrud KE, Walczak TS, Blackwell T, et al.: Antiepileptic drug increases rates of bone loss in older women: A prospective study. Neurology 2004, 62:2051-2057.
30. Pack AM: Bone health in people with epilepsy: Is it impaired and what are the risk factors? Seizure 2008, 17:181-186.
31. Souverein PC, Webb DJ, Weil JG, et al.: Use of antiepileptic drugs and risk of fractures: Case control study among patients with epilepsy. Neurology 2006, 66:1318-1324.
32. Mikati MA, Dib L, Yamout B, et al.: Two randomized vitamin D trials in ambulatory patients on anticonvulsants: Impact on bone. Neurology 2006, 67:2005-2014.
33. Ficker DM, Privitera M, Krauss G, et al.: Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 2005, 65:593-595.
34. Hakimi AS, Spanaki MV, Schuh LA, et al.: A survey of neurologists' views on epilepsy surgery and medically refractory epilepsy. Epilepsy Behav 2008, 13:96-101.
35. Engel J, Wiebe S, French J. et al.: Practice parameter: Temporal lobe and localized neocortical resections for epilepsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology, in Association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003, 60:538-547.
36. Langfitt JT, Weibe S: Early surgical treatment for epilepsy. Curr Opin Neurol 2008, 21:179-183.
37. Tellez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, Wiebe S: Long-term outcomes in epilepsy surgery: Antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain 2007, 130:334-345.
38. Spencer S: Outcomes of epilepsy surgery in adults and children. Lancet Neurol 2008, 7:525-537.
39. Wiebe S, Blume WT, Girvin JP, Eliasziw M: A randomized controlled trial of surgery for temporal lobe epilepsy. N Engl J Med 2001, 345:311-318.
40. Tanriverdi T, Olivier A, Poulin N, et al.: Long-term seizure outcome after mesial temporal lobe epilepsy surgery: corticalamygdalohippocampectomy versus selective amygdalohippocampectomy. J Neurosurg 2008, 108:517-524.
41. Schramm J: Temporal lobe epilepsy surgery and the quest for optimal extent of resection: A review. Epilepsia 2008, 49:1296-1307.
42. Benifla M, Otsubo H, Ochi A, et al.: Multiple subpial transections in pediatric epilepsy: Indications and outcomes Childs Nerv Syst 2006, 22:992-998.
43. Schuele SU, Lüders HO: Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008, 7:514-524.
44. Ardesch JJ, Buschman HP, Wagener-Schimmel LJ, et al.: Vagus nerve stimulation for medically refractory epilepsy: A long-term follow-up study. Seizure 2007, 16:579-585.
45. Cross JH, NealUEG: The ketogenic diet: update on recent clinical trials. Epilepsia 2008, 49(Suppl 8):6-10.
46. Malow BA, Foldvary-Schaefer N, Vaughn BV, et al.: Treating obstructive sleep apnea in adults with epilepsy: A randomized pilot trial. Neurology 2008, 71:572-577.
47. Foldvary-SchaeWer N, Grigg-Damberger M: Sleep and epilepsy: what we know, don't know, and need to know. J Clin Neurophysiol 2006, 23:4-20.
48. Conry JA, Pearl PL: Herbal therapy in epilepsy. In Complementary and Alternative Therapies for Epilepsy. Edited by Devinsky O, Schachter S, Pacia S. New York: Demos Medical Publishing; 2005:129-142.
49. Haller CA, Meier KH, Olson KR: Seizures reported with dietary supplements. Clin Toxicol 2005, 43:23-30.
50. Tyagi A, Delanty N: Herbal remedies, dietary supplements, and seizures. Epilepsia 2003, 44:228-235.
51. Gordon E, DevinskE O: Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001, 42:1266-1272.
52. McIntosh C, Chick J: Alcohol and the nervous system. J Neurol Neurosurg Psychiatry 2004, 7(Suppl III):16-21.
53. Data from Pivotal Study Show Medtronic Deep Brain Stimulation Therapy Reduced Seizure Rate in Patients with Severe Epilepsy [news release]. Minneapolis, MN: Medtronic, Inc.; December 8, 2008. Accessed February 2009.
54. Morrell M: Brain stimulation for epilepsy: Can scheduled or responsive neurostimulation stop seizures? Curr Opin Neurol 2006, 19:164-168.